- ⧉⌕$this->csvFile string (95) "/home/frank/public_html/ccc/application/files/2417/5932/7063/CCC_Website_Stu...
- File (54.3KB)
- Contents
-rw-r--r-- 1003 1005 54.3KB Oct 01 14:57 /home/frank/public_html/ccc/application/files/2417/5932/7063/CCC_Website_Studies_28-09-2025.csv
/home/frank/public_html/ccc/application/files/2417/5932/7063/CCC_Website_Studies_28-09-2025.csv
- ⧉⌕$csvHeaders array (8)
- ⇄0 => string (22) "Cancer Type (Optional)"$csvHeaders[0]
- ⇄1 => string (20) "Short Title/Acronym "$csvHeaders[1]
- ⇄2 => string (14) "Project Status"$csvHeaders[2]
- ⇄3 => string (10) "Full Title"$csvHeaders[3]
- ⇄4 => string (13) "Project phase"$csvHeaders[4]
- ⇄5 => string (33) "Principal Investigator (Optional)"$csvHeaders[5]
- ⇄6 => string (13) "Study Sponsor"$csvHeaders[6]
- ⇄7 => string (16) "Planned End Date"$csvHeaders[7]
- ⇄0 => string (22) "Cancer Type (Optional)"
- ⧉⌕$items array (8)
- ⇄⧉0 => array (2)$items[0]
- ⇄⧉Cancer Type (Optional) => array (30)$items[0]['Cancer Type (Optional)']
- ⇄0 => string (13) "Breast Cancer"$items[0]['Cancer Type (Optional)'][0]
- ⇄1 => string (9) "Leukaemia"$items[0]['Cancer Type (Optional)'][1]
- ⇄2 => string (18) "Head & Neck Cancer"$items[0]['Cancer Type (Optional)'][2]
- ⇄3 => string (21) "Multiple Cancer Types"$items[0]['Cancer Type (Optional)'][3]
- ⇄4 => string (12) "Liver Cancer"$items[0]['Cancer Type (Optional)'][4]
- ⇄5 => string (7) "Sarcoma"$items[0]['Cancer Type (Optional)'][5]
- ⇄6 => string (21) "Gynaecological Cancer"$items[0]['Cancer Type (Optional)'][6]
- ⇄7 => string (15) "Prostate Cancer"$items[0]['Cancer Type (Optional)'][7]
- ⇄8 => string (8) "Lymphoma"$items[0]['Cancer Type (Optional)'][8]
- ⇄9 => string (17) "Colorectal Cancer"$items[0]['Cancer Type (Optional)'][9]
- ⇄10 => string (12) "Brain Cancer"$items[0]['Cancer Type (Optional)'][10]
- ⇄11 => string (11) "Lung Cancer"$items[0]['Cancer Type (Optional)'][11]
- ⇄12 => string (14) "Bladder Cancer"$items[0]['Cancer Type (Optional)'][12]
- ⇄13 => string (20) "Stem Cell Transplant"$items[0]['Cancer Type (Optional)'][13]
- ⇄14 => string (35) "Chronic Lymphocytic Leukaemia (CLL)"$items[0]['Cancer Type (Optional)'][14]
- ⇄15 => string (8) "COVID-19"$items[0]['Cancer Type (Optional)'][15]
- ⇄16 => string (8) "Upper GI"$items[0]['Cancer Type (Optional)'][16]
- ⇄17 => string (14) "Multiple Sites"$items[0]['Cancer Type (Optional)'][17]
- ⇄18 => string (22) "Multiple Blood Cancers"$items[0]['Cancer Type (Optional)'][18]
- ⇄19 => string (7) "Myeloma"$items[0]['Cancer Type (Optional)'][19]
- ⇄20 => string (8) "Melanoma"$items[0]['Cancer Type (Optional)'][20]
- ⇄21 => string (18) "Myeloproliferative"$items[0]['Cancer Type (Optional)'][21]
- ⇄22 => string (31) "Myelodysplastic syndromes (MDS)"$items[0]['Cancer Type (Optional)'][22]
- ⇄23 => string (4) "Lung"$items[0]['Cancer Type (Optional)'][23]
- ⇄24 => string (18) "Multiple Sclerosis"$items[0]['Cancer Type (Optional)'][24]
- ⇄25 => string (10) "HPB Cancer"$items[0]['Cancer Type (Optional)'][25]
- ⇄26 => string (7) "Imaging"$items[0]['Cancer Type (Optional)'][26]
- ⇄27 => string (9) "Melanoma "$items[0]['Cancer Type (Optional)'][27]
- ⇄28 => string (12) "Psychosocial"$items[0]['Cancer Type (Optional)'][28]
- ⇄29 => string (9) "Upper GI "$items[0]['Cancer Type (Optional)'][29]
- ⇄0 => string (13) "Breast Cancer"
- ⇄Order => integer 0$items[0]['Order']
- ⇄⧉Cancer Type (Optional) => array (30)
- ⇄⧉1 => array (2)$items[1]
- ⇄⧉Short Title/Acronym => array (205)$items[1]['Short Title/Acronym ']
- ⇄0 => string (10) "3 Pillars "$items[1]['Short Title/Acronym '][0]
- ⇄⧉1 => string (212) "A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinet...$items[1]['Short Title/Acronym '][1]
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients with HER2-Positive Advanced Solid Tumors
- ⇄2 => string (67) "A Phase 1 Study of JNJ-75276617 in Participants with Acute Leukemia"$items[1]['Short Title/Acronym '][2]
- ⇄3 => string (67) "A Phase 2 study of BNT113 in HPV16+ HNSCC patients expressing PD-L1"$items[1]['Short Title/Acronym '][3]
- ⇄4 => string (77) "A Phase I/IIa Trial of HTL0039732 in Participants with Advanced Solid Tumours"$items[1]['Short Title/Acronym '][4]
- ⇄5 => string (6) "ABC-12"$items[1]['Short Title/Acronym '][5]
- ⇄6 => string (35) "Accelerator Award Protocol PANTHR-S"$items[1]['Short Title/Acronym '][6]
- ⇄7 => string (5) "ACTOv"$items[1]['Short Title/Acronym '][7]
- ⇄8 => string (7) "ADAPT-P"$items[1]['Short Title/Acronym '][8]
- ⇄9 => string (11) "Add-Aspirin"$items[1]['Short Title/Acronym '][9]
- ⇄10 => string (12) "ALLTogether1"$items[1]['Short Title/Acronym '][10]
- ⇄11 => string (7) "ALMANAC"$items[1]['Short Title/Acronym '][11]
- ⇄12 => string (9) "APHRODITE"$items[1]['Short Title/Acronym '][12]
- ⇄13 => string (8) "APPROACH"$items[1]['Short Title/Acronym '][13]
- ⇄14 => string (10) "ARISTOCRAT"$items[1]['Short Title/Acronym '][14]
- ⇄15 => string (7) "ARTEMIA"$items[1]['Short Title/Acronym '][15]
- ⇄16 => string (7) "ARTEMIS"$items[1]['Short Title/Acronym '][16]
- ⇄17 => string (68) "Assessing Treatment response in Glioblastoma (GBM) multiforme by MRI"$items[1]['Short Title/Acronym '][17]
- ⇄18 => string (31) "ASSESS-Meso (TILT) cohort study"$items[1]['Short Title/Acronym '][18]
- ⇄19 => string (5) "ATNEC"$items[1]['Short Title/Acronym '][19]
- ⇄20 => string (10) "ATTAINMENT"$items[1]['Short Title/Acronym '][20]
- ⇄21 => string (6) "AURORA"$items[1]['Short Title/Acronym '][21]
- ⇄22 => string (7) "AXA-254"$items[1]['Short Title/Acronym '][22]
- ⇄23 => string (7) "Best-Of"$items[1]['Short Title/Acronym '][23]
- ⇄24 => string (13) "BGB-11417-301"$items[1]['Short Title/Acronym '][24]
- ⇄25 => string (68) "Biomarker Driven Antifungal Stewardship: The BioDriveAFS Trial. V1.0"$items[1]['Short Title/Acronym '][25]
- ⇄26 => string (10) "BIOPROP-20"$items[1]['Short Title/Acronym '][26]
- ⇄27 => string (46) "Breast CANcer - Risk Assessment in Young women"$items[1]['Short Title/Acronym '][27]
- ⇄28 => string (15) "Brigatinib-5007"$items[1]['Short Title/Acronym '][28]
- ⇄29 => string (13) "BRUIN-CLL-211"$items[1]['Short Title/Acronym '][29]
- ⇄30 => string (13) "Burdett Grant"$items[1]['Short Title/Acronym '][30]
- ⇄31 => string (7) "CARAMEL"$items[1]['Short Title/Acronym '][31]
- ⇄32 => string (13) "CCP-Cancer UK"$items[1]['Short Title/Acronym '][32]
- ⇄33 => string (22) "Ceralasertib (AZD6738)"$items[1]['Short Title/Acronym '][33]
- ⇄34 => string (6) "CHROME"$items[1]['Short Title/Acronym '][34]
- ⇄35 => string (6) "CIPHER"$items[1]['Short Title/Acronym '][35]
- ⇄36 => string (6) "COMICE"$items[1]['Short Title/Acronym '][36]
- ⇄37 => string (8) "CONCORDE"$items[1]['Short Title/Acronym '][37]
- ⇄38 => string (11) "COVID STAFF"$items[1]['Short Title/Acronym '][38]
- ⇄39 => string (10) "CRB-601-01"$items[1]['Short Title/Acronym '][39]
- ⇄40 => string (65) "CRUK HUNTER Accelerator delivering immunotherapy for liver cancer"$items[1]['Short Title/Acronym '][40]
- ⇄41 => string (5) "CUBIC"$items[1]['Short Title/Acronym '][41]
- ⇄42 => string (75) "Demographics and needs of patients referred to Supportive Care Teams ASSESS"$items[1]['Short Title/Acronym '][42]
- ⇄43 => string (9) "DETERMINE"$items[1]['Short Title/Acronym '][43]
- ⇄44 => string (7) "DyNAMIc"$items[1]['Short Title/Acronym '][44]
- ⇄45 => string (23) "E2-RADIatE (EORTC 1811)"$items[1]['Short Title/Acronym '][45]
- ⇄46 => string (7) "EGG-CUP"$items[1]['Short Title/Acronym '][46]
- ⇄47 => string (7) "ELEVATE"$items[1]['Short Title/Acronym '][47]
- ⇄48 => string (8) "EMITT-1 "$items[1]['Short Title/Acronym '][48]
- ⇄49 => string (71) "EP0062-101 - Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer"$items[1]['Short Title/Acronym '][49]
- ⇄⧉50 => string (124) "Exploring the experiences of people who present with metastatic spinal cord ...$items[1]['Short Title/Acronym '][50]
Exploring the experiences of people who present with metastatic spinal cord compression with a malignancy of unknown origin.
- ⇄⧉51 => string (141) "Exploring the unmet needs of adult carers supporting a family member or frie...$items[1]['Short Title/Acronym '][51]
Exploring the unmet needs of adult carers supporting a family member or friend with Head and Neck Cancer (HNC), who are 75 years and above.
- ⇄52 => string (7) "FaR-RMS"$items[1]['Short Title/Acronym '][52]
- ⇄53 => string (16) "FOxTROT Platform"$items[1]['Short Title/Acronym '][53]
- ⇄54 => string (11) "GLORA Study"$items[1]['Short Title/Acronym '][54]
- ⇄55 => string (4) "HALO"$items[1]['Short Title/Acronym '][55]
- ⇄56 => string (28) "HIV- AC: Person-centred care"$items[1]['Short Title/Acronym '][56]
- ⇄57 => string (10) "HoOP Study"$items[1]['Short Title/Acronym '][57]
- ⇄58 => string (61) "How do patients make decisions about rectal cancer treatment?"$items[1]['Short Title/Acronym '][58]
- ⇄59 => string (25) "HPB Tissue Sampling Study"$items[1]['Short Title/Acronym '][59]
- ⇄60 => string (4) "HYST"$items[1]['Short Title/Acronym '][60]
- ⇄61 => string (6) "I-CARE"$items[1]['Short Title/Acronym '][61]
- ⇄62 => string (12) "ICI Genetics"$items[1]['Short Title/Acronym '][62]
- ⇄63 => string (6) "ICONIC"$items[1]['Short Title/Acronym '][63]
- ⇄64 => string (6) "IDE009"$items[1]['Short Title/Acronym '][64]
- ⇄65 => string (10) "IDE196-002"$items[1]['Short Title/Acronym '][65]
- ⇄66 => string (6) "IMPACT"$items[1]['Short Title/Acronym '][66]
- ⇄67 => string (13) "INTER-EWING-1"$items[1]['Short Title/Acronym '][67]
- ⇄68 => string (13) "IP2 - ATLANTA"$items[1]['Short Title/Acronym '][68]
- ⇄69 => string (22) "IRONMAN Registry Study"$items[1]['Short Title/Acronym '][69]
- ⇄70 => string (71) "J2J-MC-JZLH / EMBER-4 / Imlunestrant for ER+, HER2- Early Breast Cancer"$items[1]['Short Title/Acronym '][70]
- ⇄71 => string (12) "LAGOON Trial"$items[1]['Short Title/Acronym '][71]
- ⇄72 => string (6) "LATIFY"$items[1]['Short Title/Acronym '][72]
- ⇄73 => string (67) "LECMC Biomarker Discovery Programme & Prospective Sample Collection"$items[1]['Short Title/Acronym '][73]
- ⇄74 => string (12) "LuCa-MERIT-1"$items[1]['Short Title/Acronym '][74]
- ⇄75 => string (34) "M19-388 Venetoclax Extension Study"$items[1]['Short Title/Acronym '][75]
- ⇄⧉76 => string (98) "M20-638 (EPCORE FL-1): Relapsed/Refractory Follicular Lymphoma: Epcoritamab ...$items[1]['Short Title/Acronym '][76]
M20-638 (EPCORE FL-1): Relapsed/Refractory Follicular Lymphoma: Epcoritamab in Combination with R2
- ⇄77 => string (10) "MajesTEC-9"$items[1]['Short Title/Acronym '][77]
- ⇄78 => string (58) "Managing informal care with pre-existing health conditions"$items[1]['Short Title/Acronym '][78]
- ⇄79 => string (13) "MCLA-158-CL02"$items[1]['Short Title/Acronym '][79]
- ⇄80 => string (32) "Metabolic changes at end of life"$items[1]['Short Title/Acronym '][80]
- ⇄81 => string (10) "MK2870-004"$items[1]['Short Title/Acronym '][81]
- ⇄82 => string (11) "MK-3475-905"$items[1]['Short Title/Acronym '][82]
- ⇄83 => string (10) "MK3475-D46"$items[1]['Short Title/Acronym '][83]
- ⇄84 => string (72) "MK-4280A vs Physicians Choice Chemotherapy in PD-1/L1-refractory R/R cHL"$items[1]['Short Title/Acronym '][84]
- ⇄85 => string (53) "Molecular Genetics of Adverse Drug Reactions (MOLGEN)"$items[1]['Short Title/Acronym '][85]
- ⇄86 => string (43) "MOMENT (Met nOn sMall cEll caNcer regisTry)"$items[1]['Short Title/Acronym '][86]
- ⇄87 => string (27) "MOSAICC Study (Version 1.0)"$items[1]['Short Title/Acronym '][87]
- ⇄88 => string (18) "MRI in Lung Cancer"$items[1]['Short Title/Acronym '][88]
- ⇄89 => string (42) "MRI Screening with AI; A Prospective Study"$items[1]['Short Title/Acronym '][89]
- ⇄90 => string (47) "National Radiotherapy Patient Experience Survey"$items[1]['Short Title/Acronym '][90]
- ⇄91 => string (39) "NCRN443: PREAMBLE observational myeloma"$items[1]['Short Title/Acronym '][91]
- ⇄92 => string (8) "NEOBLADE"$items[1]['Short Title/Acronym '][92]
- ⇄93 => string (52) "Neurotoxicity of immune checkpoint inhibitor therapy"$items[1]['Short Title/Acronym '][93]
- ⇄94 => string (4) "NICO"$items[1]['Short Title/Acronym '][94]
- ⇄95 => string (62) "NX-5948 in Adults with Relapsed/Refractory B-cell Malignancies"$items[1]['Short Title/Acronym '][95]
- ⇄⧉96 => string (81) "ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION S...$items[1]['Short Title/Acronym '][96]
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION Study)
- ⇄97 => string (6) "OnCoRe"$items[1]['Short Title/Acronym '][97]
- ⇄98 => string (6) "OPTIMA"$items[1]['Short Title/Acronym '][98]
- ⇄99 => string (8) "OptiMATE"$items[1]['Short Title/Acronym '][99]
- ⇄100 => string (10) "PACE-NODES"$items[1]['Short Title/Acronym '][100]
- ⇄101 => string (7) "PARABLE"$items[1]['Short Title/Acronym '][101]
- ⇄102 => string (9) "PARADIGM "$items[1]['Short Title/Acronym '][102]
- ⇄103 => string (6) "PATHOS"$items[1]['Short Title/Acronym '][103]
- ⇄104 => string (12) "PEARLS study"$items[1]['Short Title/Acronym '][104]
- ⇄105 => string (8) "PEMDA-HN"$items[1]['Short Title/Acronym '][105]
- ⇄106 => string (63) "PETNECK 2 - Feasibility Study and RCT, Version 1.0, 10-May-2021"$items[1]['Short Title/Acronym '][106]
- ⇄107 => string (6) "PETReA"$items[1]['Short Title/Acronym '][107]
- ⇄108 => string (63) "Phase 1/2 Study of IMC-F106C in Advanced PRAME-Positive Cancers"$items[1]['Short Title/Acronym '][108]
- ⇄109 => string (59) "Phase 1/2 Study of RP1 +/- other therapies in solid tumours"$items[1]['Short Title/Acronym '][109]
- ⇄110 => string (74) "Phase 3 Study of SY-1425 Plus Azacitidine in RARA-positive Higher-risk MDS"$items[1]['Short Title/Acronym '][110]
- ⇄⧉111 => string (89) "Phase I/II study of AZD5863 in adult participants with advanced or metastati...$items[1]['Short Title/Acronym '][111]
Phase I/II study of AZD5863 in adult participants with advanced or metastatic solid tumor
- ⇄112 => string (61) "Phase I/IIa study to evaluate CCS1477 in haem malignancies v1"$items[1]['Short Title/Acronym '][112]
- ⇄113 => string (46) "PINCER- Platform Study for Solid Organ Cancers"$items[1]['Short Title/Acronym '][113]
- ⇄114 => string (15) "PM1183-C-010-22"$items[1]['Short Title/Acronym '][114]
- ⇄115 => string (7) "POIESIS"$items[1]['Short Title/Acronym '][115]
- ⇄116 => string (10) "POINTER-PC"$items[1]['Short Title/Acronym '][116]
- ⇄117 => string (65) "POST study: Palliative Care and Oncology Survey on Terminology v1"$items[1]['Short Title/Acronym '][117]
- ⇄118 => string (37) "Primary vitreoretinal lymphoma (PVRL)"$items[1]['Short Title/Acronym '][118]
- ⇄119 => string (8) "PRIMER-1"$items[1]['Short Title/Acronym '][119]
- ⇄120 => string (10) "PRIMUS 001"$items[1]['Short Title/Acronym '][120]
- ⇄121 => string (25) "PRINCE (TOURIST Platform)"$items[1]['Short Title/Acronym '][121]
- ⇄122 => string (13) "PRISM-MEL-301"$items[1]['Short Title/Acronym '][122]
- ⇄123 => string (6) "PRiZM+"$items[1]['Short Title/Acronym '][123]
- ⇄124 => string (8) "PROCLIPI"$items[1]['Short Title/Acronym '][124]
- ⇄125 => string (6) "PROPEL"$items[1]['Short Title/Acronym '][125]
- ⇄126 => string (8) "PROTIEUS"$items[1]['Short Title/Acronym '][126]
- ⇄127 => string (6) "PROTIS"$items[1]['Short Title/Acronym '][127]
- ⇄128 => string (9) "QB46C-H08"$items[1]['Short Title/Acronym '][128]
- ⇄129 => string (24) "RADAR (Hodgkin Lymphoma)"$items[1]['Short Title/Acronym '][129]
- ⇄130 => string (25) "RADAR (UK-MRA Myeloma XV)"$items[1]['Short Title/Acronym '][130]
- ⇄131 => string (65) "Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489"$items[1]['Short Title/Acronym '][131]
- ⇄132 => string (9) "RC48-G001"$items[1]['Short Title/Acronym '][132]
- ⇄133 => string (57) "Real-World Patient-Reported Outcomes in ER+/HER2- aBC/mBC"$items[1]['Short Title/Acronym '][133]
- ⇄134 => string (4) "REAP"$items[1]['Short Title/Acronym '][134]
- ⇄⧉135 => string (189) "RECOmMEnD A prospective real world data evaluation of clinical outcomes in m...$items[1]['Short Title/Acronym '][135]
RECOmMEnD A prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients treated as part of triplet therapy with Darolutamide
- ⇄136 => string (6) "rEECur"$items[1]['Short Title/Acronym '][136]
- ⇄137 => string (11) "REFINE-Lung"$items[1]['Short Title/Acronym '][137]
- ⇄138 => string (8) "REFRACT "$items[1]['Short Title/Acronym '][138]
- ⇄139 => string (9) "REPRESENT"$items[1]['Short Title/Acronym '][139]
- ⇄140 => string (52) "Respiratory-Swallow Training in Head and Neck Cancer"$items[1]['Short Title/Acronym '][140]
- ⇄141 => string (7) "SAFE-DE"$items[1]['Short Title/Acronym '][141]
- ⇄142 => string (66) "SBRT Pembrolizumab in patients with Unresected Stage I or II NSCLC"$items[1]['Short Title/Acronym '][142]
- ⇄143 => string (9) "SCC-After"$items[1]['Short Title/Acronym '][143]
- ⇄144 => string (58) "SEQoL: scaled collection of QoL data among HCT recipients "$items[1]['Short Title/Acronym '][144]
- ⇄145 => string (18) "SIOP Ependymoma II"$items[1]['Short Title/Acronym '][145]
- ⇄146 => string (6) "StarMS"$items[1]['Short Title/Acronym '][146]
- ⇄147 => string (6) "STATIC"$items[1]['Short Title/Acronym '][147]
- ⇄148 => string (21) "STRASS 2 (1809-STBSG)"$items[1]['Short Title/Acronym '][148]
- ⇄149 => string (5) "SUAVE"$items[1]['Short Title/Acronym '][149]
- ⇄150 => string (6) "TACE-3"$items[1]['Short Title/Acronym '][150]
- ⇄151 => string (20) "TARGET HEAD AND NECK"$items[1]['Short Title/Acronym '][151]
- ⇄152 => string (15) "TARGET NATIONAL"$items[1]['Short Title/Acronym '][152]
- ⇄153 => string (28) "Target Vaccination Version 1"$items[1]['Short Title/Acronym '][153]
- ⇄154 => string (10) "TargetLung"$items[1]['Short Title/Acronym '][154]
- ⇄⧉155 => string (79) "Tazemetostat or placebo in combination with lenalidomide + rituximab for R/R...$items[1]['Short Title/Acronym '][155]
Tazemetostat or placebo in combination with lenalidomide + rituximab for R/R FL
- ⇄156 => string (44) "T-cell Project 2.0_Version 1.0 June 18, 2018"$items[1]['Short Title/Acronym '][156]
- ⇄157 => string (36) "TebeMRD: Tebentafusp in MRD Melanoma"$items[1]['Short Title/Acronym '][157]
- ⇄158 => string (42) "Tessa Jowell BRAIN MATRIX - Platform Study"$items[1]['Short Title/Acronym '][158]
- ⇄159 => string (17) "The iLIVE Project"$items[1]['Short Title/Acronym '][159]
- ⇄160 => string (16) "The Lupiae Study"$items[1]['Short Title/Acronym '][160]
- ⇄161 => string (60) "The Prospective Ocular Melanoma Natural History (OMNi) Study"$items[1]['Short Title/Acronym '][161]
- ⇄162 => string (22) "The UK-MPN-MF Registry"$items[1]['Short Title/Acronym '][162]
- ⇄⧉163 => string (187) "TOURIST, (PRINCE,) a platform for multiple randomised trials using advanced ...$items[1]['Short Title/Acronym '][163]
TOURIST, (PRINCE,) a platform for multiple randomised trials using advanced radiotherapy techniques to establishes the utility of thoracic radiotherapy in the treatment of stage IV NCSLC.
- ⇄164 => string (7) "TRAK-ER"$items[1]['Short Title/Acronym '][164]
- ⇄165 => string (21) "UK CLL Biobank study "$items[1]['Short Title/Acronym '][165]
- ⇄166 => string (73) "UK national retrospective data collection on outcomes of CML in pregnancy"$items[1]['Short Title/Acronym '][166]
- ⇄167 => string (5) "ViSON"$items[1]['Short Title/Acronym '][167]
- ⇄168 => string (12) "VIVO Biobank"$items[1]['Short Title/Acronym '][168]
- ⇄169 => string (13) "WMUK Registry"$items[1]['Short Title/Acronym '][169]
- ⇄170 => string (12) "XPORT-MF-034"$items[1]['Short Title/Acronym '][170]
- ⇄171 => string (5) "ZEBRA"$items[1]['Short Title/Acronym '][171]
- ⇄172 => string (22) "2693-CL-1303- ASTELLAS"$items[1]['Short Title/Acronym '][172]
- ⇄173 => string (24) "TALISMAN 64407564MMY2006"$items[1]['Short Title/Acronym '][173]
- ⇄174 => string (10) "TL-895-201"$items[1]['Short Title/Acronym '][174]
- ⇄175 => string (8) "OCULE-01"$items[1]['Short Title/Acronym '][175]
- ⇄176 => string (9) "CAPRIcorn"$items[1]['Short Title/Acronym '][176]
- ⇄177 => string (19) "Saruparib (AZD5305)"$items[1]['Short Title/Acronym '][177]
- ⇄178 => string (36) "Breaking Barriers to research access"$items[1]['Short Title/Acronym '][178]
- ⇄179 => string (9) "GLIOFOCUS"$items[1]['Short Title/Acronym '][179]
- ⇄⧉180 => string (82) "2693-CL-1303 - Astellas Pharma Global Development, Inc. - Breast cancer- 079...$items[1]['Short Title/Acronym '][180]
2693-CL-1303 - Astellas Pharma Global Development, Inc. - Breast cancer- 0798/0787
- ⇄181 => string (52) "Real World Study Dostar Rectal Cancer CUP patients? "$items[1]['Short Title/Acronym '][181]
- ⇄182 => string (13) "OPTIMISE-FLT3"$items[1]['Short Title/Acronym '][182]
- ⇄⧉183 => string (205) "Phase 3, interventional, multicentre, open-label, randomized study comparing...$items[1]['Short Title/Acronym '][183]
Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)
- ⇄184 => string (7) "GO44479"$items[1]['Short Title/Acronym '][184]
- ⇄185 => string (69) "A Phase II trial of ginisortamab in participants with metastatic PDAC"$items[1]['Short Title/Acronym '][185]
- ⇄186 => string (6) "CANTOR"$items[1]['Short Title/Acronym '][186]
- ⇄187 => string (13) "BGB-11417-302"$items[1]['Short Title/Acronym '][187]
- ⇄⧉188 => string (230) "Ph 3 Randomized Study of Bleximenib, Venetoclax and Azacitidine for the Trea...$items[1]['Short Title/Acronym '][188]
Ph 3 Randomized Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed AML Harbouring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy (cAMeLot-2)
- ⇄189 => string (6) "PORTAL"$items[1]['Short Title/Acronym '][189]
- ⇄190 => string (9) "REMYEL-AI"$items[1]['Short Title/Acronym '][190]
- ⇄⧉191 => string (178) "To investigate the feasibility of a co-produced nutritional prehabilitation ...$items[1]['Short Title/Acronym '][191]
To investigate the feasibility of a co-produced nutritional prehabilitation intervention for head and neck cancer (HNC) patients treated with radical radiotherapy (chemotherapy).
- ⇄192 => string (25) "ESPAC5 Long Term Outcomes"$items[1]['Short Title/Acronym '][192]
- ⇄193 => string (53) "Correlation of PET-CT with OAR dose from radiotherapy"$items[1]['Short Title/Acronym '][193]
- ⇄194 => string (8) "HIT-Meso"$items[1]['Short Title/Acronym '][194]
- ⇄195 => string (8) "V940-009"$items[1]['Short Title/Acronym '][195]
- ⇄196 => string (9) "PerceIVe."$items[1]['Short Title/Acronym '][196]
- ⇄197 => string (12) "AGILE CST-9a"$items[1]['Short Title/Acronym '][197]
- ⇄198 => string (16) "INDIGO Community"$items[1]['Short Title/Acronym '][198]
- ⇄⧉199 => string (80) "RB-701-01 Phase 1/2 study of CRB-701 in nectin-4 positive Advanced Solid Tum...$items[1]['Short Title/Acronym '][199]
RB-701-01 Phase 1/2 study of CRB-701 in nectin-4 positive Advanced Solid Tumours
- ⇄200 => string (65) "T-DXd control arm Real World Evidence HER2 Tissue Testing Project"$items[1]['Short Title/Acronym '][200]
- ⇄201 => string (9) "STAR-TRAP"$items[1]['Short Title/Acronym '][201]
- ⇄202 => string (66) "Understanding the Needs of Autistic Adults during Cancer Treatment"$items[1]['Short Title/Acronym '][202]
- ⇄203 => string (5) "UNITY"$items[1]['Short Title/Acronym '][203]
- ⇄204 => string (31) "SAFIR ABC-10 Precision Medicine"$items[1]['Short Title/Acronym '][204]
- ⇄0 => string (10) "3 Pillars "
- ⇄Order => integer 1$items[1]['Order']
- ⇄⧉Short Title/Acronym => array (205)
- ⇄⧉2 => array (2)$items[2]
- ⇄⧉Project Status => array (2)$items[2]['Project Status']
- ⇄0 => string (4) "Open"$items[2]['Project Status'][0]
- ⇄1 => string (6) "Closed"$items[2]['Project Status'][1]
- ⇄0 => string (4) "Open"
- ⇄Order => integer 2$items[2]['Order']
- ⇄⧉Project Status => array (2)
- ⇄⧉3 => array (2)$items[3]
- ⇄⧉Full Title => array (204)$items[3]['Full Title']
- ⇄0 => binary string (199)$items[3]['Full Title'][0]
- ⇄⧉1 => string (212) "A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinet...$items[3]['Full Title'][1]
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients with HER2-Positive Advanced Solid Tumors
- ⇄⧉2 => string (107) "A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in P...$items[3]['Full Title'][2]
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
- ⇄⧉3 => string (318) "An open label Phase II randomized trial of BNT113 in combination with pembro...$items[3]['Full Title'][3]
An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1.
- ⇄⧉4 => string (191) "A Cancer Research UK Phase I/IIa Trial of HTL0039732, given Orally as Monoth...$items[3]['Full Title'][4]
A Cancer Research UK Phase I/IIa Trial of HTL0039732, given Orally as Monotherapy and in Combination with Immunotherapy or Other Approved Therapies in Participants with Advanced Solid Tumours
- ⇄⧉5 => string (160) "Exploring the microbiome in patients with advanced biliary tract cancer in a...$items[3]['Full Title'][5]
Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine
- ⇄⧉6 => string (92) "Precision medicine approaches for neoadjuvant therapy in high?risk sarcoma p...$items[3]['Full Title'][6]
Precision medicine approaches for neoadjuvant therapy in high?risk sarcoma patients PANTHR-S
- ⇄⧉7 => string (294) "Adaptive ChemoTherapy for Ovarian cancer: A multicentre phase II randomised ...$items[3]['Full Title'][7]
Adaptive ChemoTherapy for Ovarian cancer: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer
- ⇄⧉8 => string (126) "Impact of apalutamide in metastatic hormone sensitive prostate cancer patien...$items[3]['Full Title'][8]
Impact of apalutamide in metastatic hormone sensitive prostate cancer patients, a multi-centre prospective observational study
- ⇄⧉9 => string (190) "A phase III double-blind placebo-controlled randomised trial assessing the e...$items[3]['Full Title'][9]
A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
- ⇄10 => binary string (178)$items[3]['Full Title'][10]
- ⇄⧉11 => string (94) "A real-world data and sample compendium of frail and/or multiply treated lar...$items[3]['Full Title'][11]
A real-world data and sample compendium of frail and/or multiply treated large B-cell lymphoma
- ⇄⧉12 => string (87) "A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rec...$items[3]['Full Title'][12]
A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer.
- ⇄⧉13 => string (98) "Analysis of Proton vs. Photon Radiotherapy in Oligodendroglioma and Assessme...$items[3]['Full Title'][13]
Analysis of Proton vs. Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health
- ⇄⧉14 => string (112) "A randomised phase II trial of temozolomide with or without cannabinoids in ...$items[3]['Full Title'][14]
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma
- ⇄⧉15 => string (258) "A randomized, open-label, phase 3 trial comparing the efficacy and safety of...$items[3]['Full Title'][15]
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study
- ⇄16 => string (69) "Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery"$items[3]['Full Title'][16]
- ⇄⧉17 => string (129) "Novel MRI methods to understand the mechanism of treatment response and resi...$items[3]['Full Title'][17]
Novel MRI methods to understand the mechanism of treatment response and resistance in Glioblastoma multiforme (GBM): An MRI study
- ⇄⧉18 => string (242) "A prospective observational cohort study examining the natural history of me...$items[3]['Full Title'][18]
A prospective observational cohort study examining the natural history of mesothelioma, exploring potential biomarkers and factors that may predict outcome, as well as providing a resource for future trials within a cohort. TILT Cohort study
- ⇄19 => binary string (184)$items[3]['Full Title'][19]
- ⇄⧉20 => string (232) "A modular, multi-arm, first in human trial to evaluate the safety and tolera...$items[3]['Full Title'][20]
A modular, multi-arm, first in human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies
- ⇄⧉21 => string (130) "Atezolizumab in patients with urinary tract squamous cell carcinoma:a single...$items[3]['Full Title'][21]
Atezolizumab in patients with urinary tract squamous cell carcinoma:a single arm, open label, multicentre, phase II clinical trial
- ⇄⧉22 => string (205) "A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety ...$items[3]['Full Title'][22]
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- ⇄⧉23 => string (163) "Phase III study assessing the 'Best-Of' radiotherapy compared to the 'Best-O...$items[3]['Full Title'][23]
Phase III study assessing the 'Best-Of' radiotherapy compared to the 'Best-Of' surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma
- ⇄⧉24 => string (211) "A Phase 3, Open-label, Randomized Study of BGB-11417 plus Zanubrutinib Compa...$items[3]['Full Title'][24]
A Phase 3, Open-label, Randomized Study of BGB-11417 plus Zanubrutinib Compared with Venetoclax plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
- ⇄25 => binary string (159)$items[3]['Full Title'][25]
- ⇄26 => string (53) "Biologically optimised IMRT for Prostate Radiotherapy"$items[3]['Full Title'][26]
- ⇄⧉27 => string (184) "A Case Control Study of women aged 30-39 to augment breast cancer risk predi...$items[3]['Full Title'][27]
A Case Control Study of women aged 30-39 to augment breast cancer risk prediction and assess acceptability and preference of a systematic risk prediction approach through primary care.
- ⇄⧉28 => string (221) "A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in...$items[3]['Full Title'][28]
A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-Authorisation Safety Study
- ⇄⧉29 => string (285) "A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety o...$items[3]['Full Title'][29]
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor
- ⇄⧉30 => string (145) "Exploring the impact of the COVID-19 pandemic on the psychological well-bein...$items[3]['Full Title'][30]
Exploring the impact of the COVID-19 pandemic on the psychological well-being of nurses working in the cancer setting across Cheshire and Mersey
- ⇄⧉31 => string (122) "Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients ...$items[3]['Full Title'][31]
Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients with Previously Untreated Mantle Cell Lymphoma
- ⇄32 => binary string (170) "CCP-Cancer UK: Clinical Characterisation Protocol for Severe Emerging Infect...$items[3]['Full Title'][32]
- ⇄⧉33 => string (260) "A Phase I, Open-label Study to Assess the Absolute Bioavailability of Cerala...$items[3]['Full Title'][33]
A Phase I, Open-label Study to Assess the Absolute Bioavailability of Ceralasertib (AZD6738) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Ceralasertib in Patients with Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer
- ⇄⧉34 => string (253) "Phase II study of the use of neoadjuvant cabazitaxel with hormonal treatment...$items[3]['Full Title'][34]
Phase II study of the use of neoadjuvant cabazitaxel with hormonal treatment in patients with high risk operable cancer, to assess the efficacy and toxicity of cabazitaxel, and, to explore potential predictive and prognostic markers of clinical outcome.
- ⇄⧉35 => string (161) "Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients...$items[3]['Full Title'][35]
Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases
- ⇄⧉36 => string (146) "A randomized double blind placebo controlled Phase II clinical trial of Cedi...$items[3]['Full Title'][36]
A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.
- ⇄⧉37 => string (126) "A platform study of DNA damage response inhibitors in combination with conve...$items[3]['Full Title'][37]
A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer
- ⇄⧉38 => string (101) "Exploring the impact of COVID-19 on the psychological well-being of oncology...$items[3]['Full Title'][38]
Exploring the impact of COVID-19 on the psychological well-being of oncology healthcare professionals
- ⇄⧉39 => string (170) "A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy o...$items[3]['Full Title'][39]
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody against Integrin avb8, in Patients with Advanced Solid Tumors
- ⇄⧉40 => string (256) "HUNTER: Hepatocellular Carcinoma Expediter Network - created to define the h...$items[3]['Full Title'][40]
HUNTER: Hepatocellular Carcinoma Expediter Network - created to define the hepatocellular carcinoma immune environment, the key mechanisms and biomarkers, and to develop the pre-clinical models needed, to deliver immunotherapy to patients with liver cancer
- ⇄⧉41 => string (158) "CUBIC: A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination wi...$items[3]['Full Title'][41]
CUBIC: A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with Durvalumab (MEDI4736), in patients with advanced Hepatocellular Carcinoma (HCC)
- ⇄42 => string (75) "Demographics and needs of patients referred to Supportive Care Teams ASSESS"$items[3]['Full Title'][42]
- ⇄⧉43 => string (146) "Determining Extended Therapeutic indications for Existing drugs in Rare Mole...$items[3]['Full Title'][43]
Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly defined Indications using a National Evaluation platform trial
- ⇄44 => string (69) "Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy"$items[3]['Full Title'][44]
- ⇄45 => binary string (62)$items[3]['Full Title'][45]
- ⇄46 => string (63) "Enabling Genomic Testing in Cancer of Unknown Primary (EGG-CUP)"$items[3]['Full Title'][46]
- ⇄⧉47 => string (162) "A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of E...$items[3]['Full Title'][47]
A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
- ⇄⧉48 => string (204) "A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate t...$items[3]['Full Title'][48]
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies.
- ⇄⧉49 => string (256) "A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and...$items[3]['Full Title'][49]
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability ,Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
- ⇄⧉50 => string (124) "Exploring the experiences of people who present with metastatic spinal cord ...$items[3]['Full Title'][50]
Exploring the experiences of people who present with metastatic spinal cord compression with a malignancy of unknown origin.
- ⇄⧉51 => string (139) "Exploring the unmet needs of adult carers supporting a family member or frie...$items[3]['Full Title'][51]
Exploring the unmet needs of adult carers supporting a family member or friend with Head and Neck Cancer (HNC), who are 75 years and above.
- ⇄⧉52 => string (98) "FaR-RMS: An overarching study for children and adults with Frontline and Rel...$items[3]['Full Title'][52]
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
- ⇄⧉53 => string (125) "FOxTROT: Personalising neo-adjuvant Chemotherapy in Locally advanced but ope...$items[3]['Full Title'][53]
FOxTROT: Personalising neo-adjuvant Chemotherapy in Locally advanced but operable colon cancer. A randomised trial programme.
- ⇄⧉54 => string (191) "A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of...$items[3]['Full Title'][54]
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- ⇄⧉55 => string (199) "A Post-authorization Safety Study to Evaluate the Incidence of and Risk Fact...$items[3]['Full Title'][55]
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
- ⇄⧉56 => string (127) "Living with HIV and treated for Anal Cancer: an exploratory study using a co...$items[3]['Full Title'][56]
Living with HIV and treated for Anal Cancer: an exploratory study using a co-production approach to deliver person-centred care
- ⇄57 => string (65) "Hodgkin Lymphoma in Older Patients (HoOP) - A Retrospective Study"$items[3]['Full Title'][57]
- ⇄58 => string (61) "How do patients make decisions about rectal cancer treatment?"$items[3]['Full Title'][58]
- ⇄59 => string (68) "Proteomic and genomic assessment of hepatopancreaticobiliary cancers"$items[3]['Full Title'][59]
- ⇄⧉60 => string (109) "Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical I...$items[3]['Full Title'][60]
Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- ⇄61 => binary string (132) "InCreAsing Retention of healthcare staff from Ethnic minority groups (I-CARE...$items[3]['Full Title'][61]
- ⇄⧉62 => string (89) "Identification of genetic factors that predispose to immune checkpoint inhib...$items[3]['Full Title'][62]
Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity
- ⇄63 => string (56) "Improving outcomes through collaboration in osteosarcoma"$items[3]['Full Title'][63]
- ⇄64 => string (78) "(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA"$items[3]['Full Title'][64]
- ⇄65 => binary string (161)$items[3]['Full Title'][65]
- ⇄⧉66 => string (206) "IMmunotherapy and PAlliative Care Trajectories (IMPACT): A mixed methods stu...$items[3]['Full Title'][66]
IMmunotherapy and PAlliative Care Trajectories (IMPACT): A mixed methods study mapping illness trajectories for people with advanced cancer receiving immunotherapy treatment to identify palliative care need
- ⇄67 => binary string (104) "International Clinical Research Programme to Improve Outcomes in Newly Diagn...$items[3]['Full Title'][67]
- ⇄⧉68 => string (125) "ATLANTA - Additional Treatments to the Local tumour for metastatic prostate ...$items[3]['Full Title'][68]
ATLANTA - Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms
- ⇄⧉69 => string (118) "Prostate Cancer Outcomes: An International Registry to Improve Outcomes in M...$items[3]['Full Title'][69]
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)
- ⇄⧉70 => string (269) "EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs...$items[3]['Full Title'][70]
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
- ⇄71 => binary string (253) "A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Sing...$items[3]['Full Title'][71]
- ⇄⧉72 => string (314) "A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus ...$items[3]['Full Title'][72]
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
- ⇄⧉73 => string (118) "Liverpool Experimental Cancer Medicine Centre (LECMC) Biomarker Discovery Pr...$items[3]['Full Title'][73]
Liverpool Experimental Cancer Medicine Centre (LECMC) Biomarker Discovery Programme and Prospective Sample Collection
- ⇄⧉74 => string (223) "LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial ev...$items[3]['Full Title'][74]
LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
- ⇄⧉75 => string (98) "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Ven...$items[3]['Full Title'][75]
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
- ⇄⧉76 => string (215) "A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab i...$items[3]['Full Title'][76]
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
- ⇄⧉77 => string (318) "A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalido...$items[3]['Full Title'][77]
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
- ⇄⧉78 => string (126) "How is informal care to a person with cancer managed, when the person provid...$items[3]['Full Title'][78]
How is informal care to a person with cancer managed, when the person providing support has a pre-existing health condition/s?
- ⇄79 => binary string (266) "A phase 3 open-label, randomized, controlled study to evaluate the efficacy ...$items[3]['Full Title'][79]
- ⇄80 => string (69) "Investigation of biological changes in cancer towards the end of life"$items[3]['Full Title'][80]
- ⇄⧉81 => string (233) "A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxe...$items[3]['Full Title'][81]
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations
- ⇄⧉82 => string (270) "A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembroli...$items[3]['Full Title'][82]
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
- ⇄⧉83 => string (333) "An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlle...$items[3]['Full Title'][83]
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
- ⇄84 => binary string (227) " A Phase 3 Randomized Clinical Study of MK?4280A (coformulated favezelimab [...$items[3]['Full Title'][84]
- ⇄⧉85 => string (101) "Molecular genetics of adverse drug reactions: from candidate genes to genome...$items[3]['Full Title'][85]
Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies
- ⇄⧉86 => string (164) "Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC...$items[3]['Full Title'][86]
Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations / MOMENT ((Met nOn sMall cEll caNcer regisTry))
- ⇄⧉87 => string (178) "MyelOproliferative neoplasmS: An In-depth Case-Control (MOSAICC) study: A ca...$items[3]['Full Title'][87]
MyelOproliferative neoplasmS: An In-depth Case-Control (MOSAICC) study: A case-control study of patients with Myeloproliferative neoplasms and non-blood relative/friend controls.
- ⇄88 => string (39) "MRI in Lung Cancer; a prospective study"$items[3]['Full Title'][88]
- ⇄89 => binary string (79)$items[3]['Full Title'][89]
- ⇄90 => string (47) "National Radiotherapy Patient Experience Survey"$items[3]['Full Title'][90]
- ⇄⧉91 => string (80) "PROSPECTIVE RESEARCH ASSESSMENT IN MULTIPLE MYELOMA: AN OBSERVATIONAL EVALUA...$items[3]['Full Title'][91]
PROSPECTIVE RESEARCH ASSESSMENT IN MULTIPLE MYELOMA: AN OBSERVATIONAL EVALUATION
- ⇄⧉92 => string (165) "Phase II randomised placebo controlled Neoadjuvant chemotherapy study of Nin...$items[3]['Full Title'][92]
Phase II randomised placebo controlled Neoadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive bladder cancer
- ⇄93 => string (75) "Neurotoxicity of immune checkpoint inhibitor therapy: A UK-wide case series"$items[3]['Full Title'][93]
- ⇄⧉94 => string (106) "NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint in...$items[3]['Full Title'][94]
NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
- ⇄95 => binary string (172) "A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a...$items[3]['Full Title'][95]
- ⇄⧉96 => string (177) "ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Fo...$items[3]['Full Title'][96]
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
- ⇄⧉97 => string (84) "Oncological Outcomes after Clinical Complete Response in Patients with Recta...$items[3]['Full Title'][97]
Oncological Outcomes after Clinical Complete Response in Patients with Rectal Cancer
- ⇄⧉98 => string (83) "Optimal Personalised Treatment of early breast cancer using Multiparameter A...$items[3]['Full Title'][98]
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis
- ⇄99 => binary string (154) "Optimizing MATRix as remission induction in PCNSL: De-escalated induction tr...$items[3]['Full Title'][99]
- ⇄⧉100 => string (117) "PACE-NODES: A phase III randomised trial of 5 fraction prostate SBRT versus ...$items[3]['Full Title'][100]
PACE-NODES: A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT
- ⇄⧉101 => string (94) "PARABLE: Proton beam therapy in patients with breast cancer: evaluating earl...$items[3]['Full Title'][101]
PARABLE: Proton beam therapy in patients with breast cancer: evaluating early and late effects
- ⇄⧉102 => string (98) "Plasma analysis for response assessment and to direct the management of meta...$items[3]['Full Title'][102]
Plasma analysis for response assessment and to direct the management of metastatic prostate cancer
- ⇄⧉103 => string (179) "A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatmen...$items[3]['Full Title'][103]
A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer
- ⇄⧉104 => string (109) "A Phase II/III trial of Primary radiotherapy for Androgen sensitive Prostate...$items[3]['Full Title'][104]
A Phase II/III trial of Primary radiotherapy for Androgen sensitive Prostate cancer patients with Lymph nodes
- ⇄⧉105 => string (192) "An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pe...$items[3]['Full Title'][105]
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- ⇄⧉106 => string (122) "PETNECK 2: PET-CT guided, symptom-based, patient-initiated surveillance vers...$items[3]['Full Title'][106]
PETNECK 2: PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head and neck cancer
- ⇄⧉107 => string (144) "PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patien...$items[3]['Full Title'][107]
PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
- ⇄⧉108 => string (210) "A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as ...$items[3]['Full Title'][108]
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
- ⇄⧉109 => string (135) "An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in ...$items[3]['Full Title'][109]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
- ⇄⧉110 => string (212) "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus...$items[3]['Full Title'][110]
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
- ⇄⧉111 => string (295) "A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate...$items[3]['Full Title'][111]
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors
- ⇄⧉112 => string (148) "An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS14...$items[3]['Full Title'][112]
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.
- ⇄113 => string (78) "Temporal mapping of the tumour microenvironment in colorectal liver metastases"$items[3]['Full Title'][113]
- ⇄⧉114 => string (196) "Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in ...$items[3]['Full Title'][114]
Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
- ⇄⧉115 => string (335) "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety ...$items[3]['Full Title'][115]
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib
- ⇄116 => string (76) "Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer"$items[3]['Full Title'][116]
- ⇄⧉117 => string (117) "What do individuals known to palliative care and oncology services think abo...$items[3]['Full Title'][117]
What do individuals known to palliative care and oncology services think about the terminology used to describe them?
- ⇄118 => string (0) ""$items[3]['Full Title'][118]
- ⇄⧉119 => string (87) "Perioperative pembrolizumab and lenvatinib in Resectable Hepatocellular Carc...$items[3]['Full Title'][119]
Perioperative pembrolizumab and lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- ⇄⧉120 => string (206) "PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitax...$items[3]['Full Title'][120]
PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation
- ⇄⧉121 => string (139) "PRINCE: Prospective, randomised, multicentre trial of first line systemic tr...$items[3]['Full Title'][121]
PRINCE: Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in stage IV non-small cell lung cancer
- ⇄⧉122 => string (189) "A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Ni...$items[3]['Full Title'][122]
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- ⇄⧉123 => string (134) "PRiZM+: A phase II platform study of zanubrutinib monotherapy and combinatio...$items[3]['Full Title'][123]
PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma
- ⇄⧉124 => string (210) "Multicenter Observational Prospective Study For The Identification Of Progno...$items[3]['Full Title'][124]
Multicenter Observational Prospective Study For The Identification Of Prognostic Factors In Patients With Mycosis Fungoides/Sezary Syndrome: Proposal For An International Prognostic Index For Cutaneous Lymphoma
- ⇄⧉125 => string (89) "PROPEL: Evaluation of PeRsOnalised PrEhabilitation in people with acute myel...$items[3]['Full Title'][125]
PROPEL: Evaluation of PeRsOnalised PrEhabilitation in people with acute myeloid Leukaemia
- ⇄⧉126 => string (150) "A Randomised Phase 2 Trial Comparing Proton versus Photon Based Neoadjuvant ...$items[3]['Full Title'][126]
A Randomised Phase 2 Trial Comparing Proton versus Photon Based Neoadjuvant Chemoradiation, followed by Adjuvant Immunotherapy, in Oesophageal Cancer.
- ⇄⧉127 => string (80) "PROton beam Therapy versus Intensity-modulated radiotherapy for Sinonasal ca...$items[3]['Full Title'][127]
PROton beam Therapy versus Intensity-modulated radiotherapy for Sinonasal cancer
- ⇄⧉128 => string (143) "A Phase II, open label, single arm study to assess the efficacy of intratumo...$items[3]['Full Title'][128]
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
- ⇄⧉129 => string (174) "A randomised phase III trial with a PET response adapted design comparing AB...$items[3]['Full Title'][129]
A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
- ⇄⧉130 => string (208) "Risk-Adapted therapy Directed According to Response comparing treatment esca...$items[3]['Full Title'][130]
Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
- ⇄⧉131 => string (276) "Randomized, Double-Blind, Multicenter Phase 3 Trial ofBMS-986489 (BMS-986012...$items[3]['Full Title'][131]
Randomized, Double-Blind, Multicenter Phase 3 Trial ofBMS-986489 (BMS-986012 + nivolumab FDC) incombination with Carboplatin plus Etoposide vsAtezolizumab in combination with Carboplatin plusEtoposide as First-line Therapy in Extensive-StageSmall Cell Lung Cancer (CA245-0001)
- ⇄⧉132 => string (228) "A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating t...$items[3]['Full Title'][132]
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma
- ⇄⧉133 => string (83) "Real-World Patient-Reported Outcomes in ER+/HER2- Advanced/Metastatic Breast...$items[3]['Full Title'][133]
Real-World Patient-Reported Outcomes in ER+/HER2- Advanced/Metastatic Breast Cancer
- ⇄⧉134 => string (90) "Reducing Emergency Admissions for Patients with Cancer Complications and/or ...$items[3]['Full Title'][134]
Reducing Emergency Admissions for Patients with Cancer Complications and/or Co-morbidities
- ⇄⧉135 => string (189) "RECOmMEnD A prospective real world data evaluation of clinical outcomes in m...$items[3]['Full Title'][135]
RECOmMEnD A prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients treated as part of triplet therapy with Darolutamide
- ⇄⧉136 => string (125) "International randomised controlled trial of chemotherapy for the treatment ...$items[3]['Full Title'][136]
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
- ⇄⧉137 => string (241) "A randomised open-label phase III trial of Reduced Frequency pembrolizumab i...$items[3]['Full Title'][137]
A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design
- ⇄⧉138 => string (204) "Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy ...$items[3]['Full Title'][138]
Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy (REFRACT): A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms
- ⇄⧉139 => string (154) "Exploring Barriers to Recruiting Underrepresented Groups to Bladder and Head...$items[3]['Full Title'][139]
Exploring Barriers to Recruiting Underrepresented Groups to Bladder and Head & Neck Oncology Trials: A Mixed-methods Approach to Increasing Representation
- ⇄⧉140 => string (149) "Development and feasibility of a respiratory-swallow training intervention t...$items[3]['Full Title'][140]
Development and feasibility of a respiratory-swallow training intervention to improve swallow function for people with head and neck cancer (ReST-HN)
- ⇄141 => string (60) "Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer"$items[3]['Full Title'][141]
- ⇄⧉142 => string (268) "A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Saf...$items[3]['Full Title'][142]
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- ⇄⧉143 => string (181) "Adjuvant Radiotherapy in Patients with High-risk Primary Cutaneous Squamous ...$items[3]['Full Title'][143]
Adjuvant Radiotherapy in Patients with High-risk Primary Cutaneous Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): An Open Label, Multicentre, Two-arm Phase III Randomised trial.
- ⇄⧉144 => string (131) "Scaled collection of socioEconomic and Quality of Life data from patients un...$items[3]['Full Title'][144]
Scaled collection of socioEconomic and Quality of Life data from patients undergoing allogeneic haematopoietic cell transplantation
- ⇄⧉145 => string (144) "SIOP Ependymoma II - An International Clinical Program for the diagnosis and...$items[3]['Full Title'][145]
SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma
- ⇄⧉146 => string (200) "A multicentre, randomised controlled trial to evaluate the efficacy of autol...$items[3]['Full Title'][146]
A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.
- ⇄⧉147 => string (127) "A Randomised Phase III Trial Comparing Intermittent with Continuous Treatmen...$items[3]['Full Title'][147]
A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
- ⇄⧉148 => string (149) "A randomized phase III study of neoadjuvant chemotherapy followed by surgery...$items[3]['Full Title'][148]
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma
- ⇄⧉149 => string (119) "A Randomised Phase II Study of Sunitinib versus Dacarbazine in the Treatment...$items[3]['Full Title'][149]
A Randomised Phase II Study of Sunitinib versus Dacarbazine in the Treatment of Patients with Metastatic Uveal Melanoma
- ⇄⧉150 => string (158) "TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial ...$items[3]['Full Title'][150]
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC
- ⇄151 => string (65) "Tissue analysis for stratifying therapy in head and neck diseases"$items[3]['Full Title'][151]
- ⇄⧉152 => string (83) "Tumour Characterisation to Guide Experimental Targeted Therapy - National Ex...$items[3]['Full Title'][152]
Tumour Characterisation to Guide Experimental Targeted Therapy - National Expansion
- ⇄⧉153 => string (96) "Evaluation of response to routine vaccination to assess immunocompetence in ...$items[3]['Full Title'][153]
Evaluation of response to routine vaccination to assess immunocompetence in patients with cancer
- ⇄154 => string (70) "Tissue analysis for stratifying therapy in proliferative lung diseases"$items[3]['Full Title'][154]
- ⇄⧉155 => string (208) "A phase 1B/3 double-blind, randomized, active-controlled, adaptive study of ...$items[3]['Full Title'][155]
A phase 1B/3 double-blind, randomized, active-controlled, adaptive study of tazemetostat or placebo in combination with Lenalidomide plus Rituximab in participants with relapsed/refractory follicular lymphoma
- ⇄⧉156 => string (113) "PROSPECTIVE OBSERVATIONAL INTERNATIONAL COHORT STUDY OF PATIENTS WITH NEWLY ...$items[3]['Full Title'][156]
PROSPECTIVE OBSERVATIONAL INTERNATIONAL COHORT STUDY OF PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T CELL LYMPHOMA.
- ⇄⧉157 => string (143) "A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and ...$items[3]['Full Title'][157]
A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma with Molecular Relapsed Disease
- ⇄⧉158 => string (309) "A British feasibility study of molecular stratification and targeted therapy...$items[3]['Full Title'][158]
A British feasibility study of molecular stratification and targeted therapy to optimize the clinical management of patients with glioma by enhancing clinical outcomes, Reducing avoidable toxicity, improving management of post-operative residual & recurrent disease and improving survivorship - Platform Study
- ⇄⧉159 => string (93) "The iLIVE project: Live well, die well. A research programme to support livi...$items[3]['Full Title'][159]
The iLIVE project: Live well, die well. A research programme to support living until the end.
- ⇄⧉160 => string (128) "The Lupiae Study Towards personalized medicine for refractory relapsed Folli...$items[3]['Full Title'][160]
The Lupiae Study Towards personalized medicine for refractory relapsed Follicular Lymphoma patients: the Cantera Lupiae registry
- ⇄161 => string (54) "A Prospective Natural History Study in Uveal Melanoma."$items[3]['Full Title'][161]
- ⇄162 => string (63) "The UK Myeloproliferative Neoplasms Registry for Myelofibrosis "$items[3]['Full Title'][162]
- ⇄⧉163 => string (177) "TOURIST, a platform for multiple randomised trials using advanced radiothera...$items[3]['Full Title'][163]
TOURIST, a platform for multiple randomised trials using advanced radiotherapy techniques to establishes the utility of thoracic radiotherapy in the treatment of stage IV NCSLC.
- ⇄⧉164 => string (234) "A randomised trial of early detection of molecular relapse with circulating ...$items[3]['Full Title'][164]
A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER positive HER2 negative breast cancer
- ⇄165 => string (21) "UK CLL Biobank study "$items[3]['Full Title'][165]
- ⇄166 => string (73) "UK national retrospective data collection on outcomes of CML in pregnancy"$items[3]['Full Title'][166]
- ⇄⧉167 => string (90) "VOLATILE ORGANIC COMPOUNDS AS BREATH BIOMARKERS IN SQUAMOUS OESOPHAGEAL NEOP...$items[3]['Full Title'][167]
VOLATILE ORGANIC COMPOUNDS AS BREATH BIOMARKERS IN SQUAMOUS OESOPHAGEAL NEOPLASMS (ViSON)
- ⇄168 => string (33) "VIVO Biobank Research Tissue Bank"$items[3]['Full Title'][168]
- ⇄169 => binary string (77)$items[3]['Full Title'][169]
- ⇄170 => binary string (187) "A Phase 1/2 Study of to evaluate safety and efficacy of selinexor, a selecti...$items[3]['Full Title'][170]
- ⇄⧉171 => string (179) "Zanubrutinib plus rituximab (Zanu-R) as fixed duration, early intervention v...$items[3]['Full Title'][171]
Zanubrutinib plus rituximab (Zanu-R) as fixed duration, early intervention versus observation for patients with indolent mantle cell lymphoma: a randomised phase II clinical trial
- ⇄⧉172 => string (306) "A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to In...$items[3]['Full Title'][172]
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
- ⇄⧉173 => string (115) "A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventio...$items[3]['Full Title'][173]
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-Related Oral Toxicity
- ⇄⧉174 => string (234) "A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory M...$items[3]['Full Title'][174]
A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
- ⇄⧉175 => string (175) "A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-...$items[3]['Full Title'][175]
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
- ⇄⧉176 => string (93) "Cardiac Assessment of Patients Receiving Inhibitors of B-cell Receptor Signa...$items[3]['Full Title'][176]
Cardiac Assessment of Patients Receiving Inhibitors of B-cell Receptor Signalling (CAPRIcorn)
- ⇄⧉177 => string (232) "A Phase I, Open-label Study to Assess the Absolute Bioavailability of Sarupa...$items[3]['Full Title'][177]
A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients with Advanced Solid Malignancies
- ⇄178 => string (74) "Understanding and Breaking Barriers to Research Access for Cancer Patients"$items[3]['Full Title'][178]
- ⇄⧉179 => string (195) "A Phase 3, open-label, randomized 2-arm study comparing the clinical efficac...$items[3]['Full Title'][179]
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma
- ⇄⧉180 => string (156) "A Real-world Study to Evaluate Clinical Outcomes of dostarlimab in Patients ...$items[3]['Full Title'][180]
A Real-world Study to Evaluate Clinical Outcomes of dostarlimab in Patients with Previously Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
- ⇄181 => string (58) "Optimising Therapy in FLT3-mutated Acute Myeloid Leukaemia"$items[3]['Full Title'][181]
- ⇄⧉182 => string (205) "Phase 3, interventional, multicentre, open-label, randomized study comparing...$items[3]['Full Title'][182]
Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)
- ⇄⧉183 => string (229) "A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SA...$items[3]['Full Title'][183]
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA
- ⇄⧉184 => string (371) "A Cancer Research UK Phase II open label trial in participants with metastat...$items[3]['Full Title'][184]
A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously with i) first-line standard of care nab-paclitaxel and gemcitabine or ii) randomised to MEK inhibitor maintenance therapy or observation, in participants who have responded to a first-line standard of care induction regimen
- ⇄⧉185 => string (249) "Substudy 1: Metastatic Colorectal Cancer Without Liver Metastases A Phase II...$items[3]['Full Title'][185]
Substudy 1: Metastatic Colorectal Cancer Without Liver Metastases A Phase II, Open-Label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR)
- ⇄⧉186 => string (173) "A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax PlusZanub...$items[3]['Full Title'][186]
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax PlusZanubrutinib Versus Placebo Plus Zanubrutinib in Patients WithRelapsed/Refractory Mantle Cell Lymphoma
- ⇄⧉187 => string (277) "A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib,...$items[3]['Full Title'][187]
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harbouring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
- ⇄⧉188 => string (133) "A phase II trial of polatuzumab vedotin, obinutuzumab and glofitamab as a pe...$items[3]['Full Title'][188]
A phase II trial of polatuzumab vedotin, obinutuzumab and glofitamab as a peri-CAR-T cell treatment strategy in large B-cell lymphoma
- ⇄⧉189 => string (85) "Deep Real-World Data Study in Myelofibrosis Using Artificial Intelligence (R...$items[3]['Full Title'][189]
Deep Real-World Data Study in Myelofibrosis Using Artificial Intelligence (REMYEL-AI)
- ⇄⧉190 => string (182) "To investigate the feasibility of a co-produced nutritional prehabilitation ...$items[3]['Full Title'][190]
To investigate the feasibility of a co-produced nutritional prehabilitation intervention for head and neck cancer (HNC) patients treated with radical radiotherapy (+/- chemotherapy).
- ⇄⧉191 => string (80) "Long term overall and disease-free survival in participants of the ESPAC5 tr...$items[3]['Full Title'][191]
Long term overall and disease-free survival in participants of the ESPAC5 trial.
- ⇄⧉192 => string (105) "Correlation of baseline PET-CT parameters with subsequent radiotherapy dose ...$items[3]['Full Title'][192]
Correlation of baseline PET-CT parameters with subsequent radiotherapy dose to organs in Hodgkin lymphoma
- ⇄193 => string (78) "Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma"$items[3]['Full Title'][193]
- ⇄⧉194 => string (266) "Phase 3 Randomized Double-blind Placebo-controlled Study of Adjuvant Pembrol...$items[3]['Full Title'][194]
Phase 3 Randomized Double-blind Placebo-controlled Study of Adjuvant Pembrolizumab W/WO V940 in Resectable Stages II-IIIB(N2) NSCLC for patients not achieving pCR after receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery
- ⇄⧉195 => string (93) "Power of liquid biopsy tracking in immunotherapy treated stage III and IV me...$items[3]['Full Title'][195]
Power of liquid biopsy tracking in immunotherapy treated stage III and IV melanoma (PerceIVe)
- ⇄⧉196 => string (232) "A Multicentre, Adaptive Phase II Platform Trial to Evaluate the Safety, Effi...$items[3]['Full Title'][196]
A Multicentre, Adaptive Phase II Platform Trial to Evaluate the Safety, Efficacy and Virological response of ALG-097558 as monotherapy and in combination with Remdesivir in high-risk population for the Treatment of COVID-19 disease.
- ⇄⧉197 => string (347) "INDIGO Community: Investigating DIGital Outcomes in a community setting for ...$items[3]['Full Title'][197]
INDIGO Community: Investigating DIGital Outcomes in a community setting for patients living with and beyond a diagnosis of cancer. To understand more about the long-term outcomes and service use of patients living with and beyond a diagnosis of cancer Phase II randomised feasibility research administering questionnaires in a mixed methods study.
- ⇄⧉198 => string (173) "A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy ...$items[3]['Full Title'][198]
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
- ⇄⧉199 => string (132) "T-DXd Pan-tumor EC study - External Control Arm Study to Support HTA Submiss...$items[3]['Full Title'][199]
T-DXd Pan-tumor EC study - External Control Arm Study to Support HTA Submissions for T-DXd for Patients with HER2 IHC3+ Solid Tumors
- ⇄200 => binary string (182) "STAR-TRAP: Phase II clinical trial of using stereotactic body radiotherapy (...$items[3]['Full Title'][200]
- ⇄⧉201 => string (79) "Understanding the Needs of Autistic Adults with Cancer during Cancer Treatme...$items[3]['Full Title'][201]
Understanding the Needs of Autistic Adults with Cancer during Cancer Treatment
- ⇄⧉202 => string (90) "Understanding the Needs and Interactions between Ethnicity, Cancer and Comor...$items[3]['Full Title'][202]
Understanding the Needs and Interactions between Ethnicity, Cancer and Comorbid Conditions
- ⇄⧉203 => string (167) "Molecular targeted maintenance therapy versus standard of care in advanced b...$items[3]['Full Title'][203]
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
- ⇄0 => binary string (199)
- ⇄Order => integer 3$items[3]['Order']
- ⇄⧉Full Title => array (204)
- ⇄⧉4 => array (2)$items[4]
- ⇄⧉Project phase => array (12)$items[4]['Project phase']
- ⇄0 => string (7) "Phase 2"$items[4]['Project phase'][0]
- ⇄1 => string (7) "Phase 1"$items[4]['Project phase'][1]
- ⇄2 => string (7) "Phase I"$items[4]['Project phase'][2]
- ⇄3 => string (9) "Phase I/2"$items[4]['Project phase'][3]
- ⇄4 => string (14) "Not Applicable"$items[4]['Project phase'][4]
- ⇄5 => string (0) ""$items[4]['Project phase'][5]
- ⇄6 => string (7) "Phase 3"$items[4]['Project phase'][6]
- ⇄7 => string (17) "Pilot/Feasibility"$items[4]['Project phase'][7]
- ⇄8 => string (9) "Phase 2/3"$items[4]['Project phase'][8]
- ⇄9 => string (9) "Phase 1/2"$items[4]['Project phase'][9]
- ⇄10 => string (5) "Study"$items[4]['Project phase'][10]
- ⇄11 => string (21) "Experimental Medicine"$items[4]['Project phase'][11]
- ⇄0 => string (7) "Phase 2"
- ⇄Order => integer 4$items[4]['Order']
- ⇄⧉Project phase => array (12)
- ⇄⧉5 => array (2)$items[5]
- ⇄⧉Principal Investigator (Optional) => array (61)$items[5]['Principal Investigator (Optional)']
- ⇄⧉0 => string (21) "Prof Carlo Palmieri "$items[5]['Principal Investigator (Optional)'][0]
Prof Carlo Palmieri
- ⇄1 => string (16) "Dr Thomas Seddon"$items[5]['Principal Investigator (Optional)'][1]
- ⇄2 => string (26) "Prof Christian Ottensmeier"$items[5]['Principal Investigator (Optional)'][2]
- ⇄3 => string (18) "Prof Daniel Palmer"$items[5]['Principal Investigator (Optional)'][3]
- ⇄4 => string (17) "Dr Olusola Faluyi"$items[5]['Principal Investigator (Optional)'][4]
- ⇄⧉5 => string (13) "Dr Nasim Ali"$items[5]['Principal Investigator (Optional)'][5]
Dr Nasim Ali
- ⇄6 => string (14) "Dr Rosie Lord "$items[5]['Principal Investigator (Optional)'][6]
- ⇄7 => string (18) "Dr Isabel Syndikus"$items[5]['Principal Investigator (Optional)'][7]
- ⇄8 => string (20) "Dr Arpad (Gabe) Toth"$items[5]['Principal Investigator (Optional)'][8]
- ⇄9 => string (15) "Dr Vikram Singh"$items[5]['Principal Investigator (Optional)'][9]
- ⇄10 => string (17) "Dr Amir Montazeri"$items[5]['Principal Investigator (Optional)'][10]
- ⇄11 => string (16) "Dr Shaveta Mehta"$items[5]['Principal Investigator (Optional)'][11]
- ⇄12 => string (16) "Dr Carles Escriu"$items[5]['Principal Investigator (Optional)'][12]
- ⇄13 => string (12) "Dr Tony Pope"$items[5]['Principal Investigator (Optional)'][13]
- ⇄14 => string (15) "Dr Joachim Chan"$items[5]['Principal Investigator (Optional)'][14]
- ⇄15 => string (16) "Dr Muhammad Saif"$items[5]['Principal Investigator (Optional)'][15]
- ⇄⧉16 => string (17) "Dr Aditya Shenoy"$items[5]['Principal Investigator (Optional)'][16]
Dr Aditya Shenoy
- ⇄17 => string (18) "Dr Stella Williams"$items[5]['Principal Investigator (Optional)'][17]
- ⇄18 => string (17) "Dr Lynda Appleton"$items[5]['Principal Investigator (Optional)'][18]
- ⇄19 => string (13) "Dr Matt Wells"$items[5]['Principal Investigator (Optional)'][19]
- ⇄20 => string (14) "Dr Zafar Malik"$items[5]['Principal Investigator (Optional)'][20]
- ⇄21 => string (14) "Dr Dan Monnery"$items[5]['Principal Investigator (Optional)'][21]
- ⇄⧉22 => string (16) "Dr Shobha Silva"$items[5]['Principal Investigator (Optional)'][22]
Dr Shobha Silva
- ⇄23 => string (17) "Dr Anoop Haridass"$items[5]['Principal Investigator (Optional)'][23]
- ⇄24 => string (15) "Dr Eliyaz Ahmed"$items[5]['Principal Investigator (Optional)'][24]
- ⇄25 => string (12) " Kate Parker"$items[5]['Principal Investigator (Optional)'][25]
- ⇄26 => string (20) "Dr Heulwen Sheldrick"$items[5]['Principal Investigator (Optional)'][26]
- ⇄27 => string (19) "Dr Gillian Brearton"$items[5]['Principal Investigator (Optional)'][27]
- ⇄⧉28 => string (19) "Mary Anthonypillai"$items[5]['Principal Investigator (Optional)'][28]
Mary Anthonypillai
- ⇄29 => string (15) "Dr Laura Cossar"$items[5]['Principal Investigator (Optional)'][29]
- ⇄30 => string (20) "Alexandra Gilbertson"$items[5]['Principal Investigator (Optional)'][30]
- ⇄⧉31 => string (17) "Dr Joseph Sacco "$items[5]['Principal Investigator (Optional)'][31]
Dr Joseph Sacco
- ⇄32 => string (16) "Dr Azman Ibrahim"$items[5]['Principal Investigator (Optional)'][32]
- ⇄⧉33 => string (15) "Dr Helen Innes"$items[5]['Principal Investigator (Optional)'][33]
Dr Helen Innes
- ⇄34 => string (17) "Prof Andy Pettitt"$items[5]['Principal Investigator (Optional)'][34]
- ⇄35 => string (18) "Dr Stephen Hawkins"$items[5]['Principal Investigator (Optional)'][35]
- ⇄36 => string (17) "Dr Rachel Brooker"$items[5]['Principal Investigator (Optional)'][36]
- ⇄37 => string (15) "Dr Seamus Coyle"$items[5]['Principal Investigator (Optional)'][37]
- ⇄38 => string (17) "Dr Matthew Howell"$items[5]['Principal Investigator (Optional)'][38]
- ⇄39 => string (16) "Dr Jeffrey Smith"$items[5]['Principal Investigator (Optional)'][39]
- ⇄40 => string (15) "Dr Rachel Wells"$items[5]['Principal Investigator (Optional)'][40]
- ⇄41 => string (18) "Prof Michael Brada"$items[5]['Principal Investigator (Optional)'][41]
- ⇄42 => string (11) "Dr Marc Rea"$items[5]['Principal Investigator (Optional)'][42]
- ⇄43 => string (13) "Louise Turtle"$items[5]['Principal Investigator (Optional)'][43]
- ⇄44 => string (15) "Mr Simon Shamas"$items[5]['Principal Investigator (Optional)'][44]
- ⇄45 => string (19) "Dr Rajaram Sripadam"$items[5]['Principal Investigator (Optional)'][45]
- ⇄46 => string (14) "Dr Shaun Tolan"$items[5]['Principal Investigator (Optional)'][46]
- ⇄47 => string (19) "Dr Caroline Brammer"$items[5]['Principal Investigator (Optional)'][47]
- ⇄48 => string (22) "Dr Arvind Arumainathan"$items[5]['Principal Investigator (Optional)'][48]
- ⇄49 => string (14) "Dr Nauman Butt"$items[5]['Principal Investigator (Optional)'][49]
- ⇄50 => string (14) "Sarah Watmough"$items[5]['Principal Investigator (Optional)'][50]
- ⇄⧉51 => string (20) "Dr Chinnamani Eswar"$items[5]['Principal Investigator (Optional)'][51]
Dr Chinnamani Eswar
- ⇄52 => string (21) "Prof Nagesh Kalakonda"$items[5]['Principal Investigator (Optional)'][52]
- ⇄53 => string (16) "Georgiana Synesi"$items[5]['Principal Investigator (Optional)'][53]
- ⇄54 => string (15) "Dr Zulfiqar Ali"$items[5]['Principal Investigator (Optional)'][54]
- ⇄55 => string (14) "Dr Nicky Thorp"$items[5]['Principal Investigator (Optional)'][55]
- ⇄56 => string (18) " Dr Ernie Marshall"$items[5]['Principal Investigator (Optional)'][56]
- ⇄57 => string (16) "Dr Alia Alchawaf"$items[5]['Principal Investigator (Optional)'][57]
- ⇄58 => string (15) "Mrs Emma Whitby"$items[5]['Principal Investigator (Optional)'][58]
- ⇄59 => string (17) "Dr Muhammad Heiba"$items[5]['Principal Investigator (Optional)'][59]
- ⇄60 => string (15) "Dr Ik Shin Chin"$items[5]['Principal Investigator (Optional)'][60]
- ⇄⧉0 => string (21) "Prof Carlo Palmieri "
- ⇄Order => integer 5$items[5]['Order']
- ⇄⧉Principal Investigator (Optional) => array (61)
- ⇄⧉6 => array (2)$items[6]
- ⇄⧉Study Sponsor => array (87)$items[6]['Study Sponsor']
- ⇄0 => string (23) "University of Liverpool"$items[6]['Study Sponsor'][0]
- ⇄1 => string (29) "Suzhou Zanrong Pharma Limited"$items[6]['Study Sponsor'][1]
- ⇄2 => string (12) "Janssen Ltd."$items[6]['Study Sponsor'][2]
- ⇄3 => string (11) "BioNTech SE"$items[6]['Study Sponsor'][3]
- ⇄4 => string (18) "Cancer Research UK"$items[6]['Study Sponsor'][4]
- ⇄5 => string (33) "The Christie NHS Foundation Trust"$items[6]['Study Sponsor'][5]
- ⇄6 => string (38) "The Royal Marsden NHS Foundation Trust"$items[6]['Study Sponsor'][6]
- ⇄7 => string (25) "University College London"$items[6]['Study Sponsor'][7]
- ⇄8 => string (30) "Karolinska University Hospital"$items[6]['Study Sponsor'][8]
- ⇄9 => string (52) "The Clatterbridge Cancer Centre NHS Foundation Trust"$items[6]['Study Sponsor'][9]
- ⇄10 => string (19) "University of Leeds"$items[6]['Study Sponsor'][10]
- ⇄11 => string (24) "University of Birmingham"$items[6]['Study Sponsor'][11]
- ⇄12 => string (22) "OSE Immunotherapeutics"$items[6]['Study Sponsor'][12]
- ⇄13 => string (23) "North Bristol NHS Trust"$items[6]['Study Sponsor'][13]
- ⇄14 => string (61) "University Hospitals of Derby and Burton NHS Foundation Trust"$items[6]['Study Sponsor'][14]
- ⇄15 => string (16) "Medannex Limited"$items[6]['Study Sponsor'][15]
- ⇄16 => string (52) "University Hospital Southampton NHS Foundation Trust"$items[6]['Study Sponsor'][16]
- ⇄17 => string (18) "Incyte Corporation"$items[6]['Study Sponsor'][17]
- ⇄18 => string (66) "EORTC - European Organisation for Research and Treatment of Cancer"$items[6]['Study Sponsor'][18]
- ⇄19 => string (11) "BeiGene Ltd"$items[6]['Study Sponsor'][19]
- ⇄20 => string (44) "Hull University Teaching Hospitals NHS Trust"$items[6]['Study Sponsor'][20]
- ⇄21 => string (48) "Manchester University NHS Foundation Trust (MFT)"$items[6]['Study Sponsor'][21]
- ⇄22 => string (6) "Takeda"$items[6]['Study Sponsor'][22]
- ⇄23 => string (30) "Eli Lilly and Company Ltd - UK"$items[6]['Study Sponsor'][23]
- ⇄24 => string (11) "AstraZeneca"$items[6]['Study Sponsor'][24]
- ⇄25 => string (26) "Corbus Pharmaceuticals Inc"$items[6]['Study Sponsor'][25]
- ⇄26 => string (40) "Newcastle Upon Tyne NHS Foundation Trust"$items[6]['Study Sponsor'][26]
- ⇄27 => string (41) "NHS Greater Glasgow and Clyde Healthboard"$items[6]['Study Sponsor'][27]
- ⇄28 => string (27) "Stemline Therapeutics, Inc."$items[6]['Study Sponsor'][28]
- ⇄29 => string (22) "Grey Wolf Therapeutics"$items[6]['Study Sponsor'][29]
- ⇄30 => string (23) "Ellipses Pharma Limited"$items[6]['Study Sponsor'][30]
- ⇄31 => string (20) "Lancaster University"$items[6]['Study Sponsor'][31]
- ⇄32 => string (26) "Ascentage Pharma Group Inc"$items[6]['Study Sponsor'][32]
- ⇄33 => string (20) "University of Oxford"$items[6]['Study Sponsor'][33]
- ⇄34 => string (23) "University of Leicester"$items[6]['Study Sponsor'][34]
- ⇄35 => string (23) "Ideaya Biosciences, Inc"$items[6]['Study Sponsor'][35]
- ⇄36 => string (23) "Imperial College London"$items[6]['Study Sponsor'][36]
- ⇄37 => string (41) "Guy's and St Thomas' NHS Foundation Trust"$items[6]['Study Sponsor'][37]
- ⇄38 => string (12) "PharmaMar SA"$items[6]['Study Sponsor'][38]
- ⇄39 => string (10) "Abbvie Inc"$items[6]['Study Sponsor'][39]
- ⇄40 => string (5) "Merus"$items[6]['Study Sponsor'][40]
- ⇄41 => string (26) "Merck Sharpe & Dohme - MSD"$items[6]['Study Sponsor'][41]
- ⇄42 => string (60) "Newham University Hospital NHS Trust,University of Liverpool"$items[6]['Study Sponsor'][42]
- ⇄43 => string (22) "University of Aberdeen"$items[6]['Study Sponsor'][43]
- ⇄44 => string (26) "Birmingham City University"$items[6]['Study Sponsor'][44]
- ⇄45 => string (20) "Bristol Myers Squibb"$items[6]['Study Sponsor'][45]
- ⇄46 => string (26) "Cardiff and Vale NHS Trust"$items[6]['Study Sponsor'][46]
- ⇄47 => string (22) "Nurix Therapeutics Inc"$items[6]['Study Sponsor'][47]
- ⇄48 => string (13) "Chimerix Inc."$items[6]['Study Sponsor'][48]
- ⇄49 => string (39) "Klinikum der Landeshauptstadt Stuttgart"$items[6]['Study Sponsor'][49]
- ⇄50 => string (28) "Institute of Cancer Research"$items[6]['Study Sponsor'][50]
- ⇄51 => string (18) "Velindre NHS Trust"$items[6]['Study Sponsor'][51]
- ⇄52 => string (21) "Flamingo Therapeutics"$items[6]['Study Sponsor'][52]
- ⇄53 => string (18) "Immunocore Limited"$items[6]['Study Sponsor'][53]
- ⇄54 => string (13) "Replimune Ltd"$items[6]['Study Sponsor'][54]
- ⇄55 => string (21) "Syros Pharmaceuticals"$items[6]['Study Sponsor'][55]
- ⇄56 => string (11) "CellCentric"$items[6]['Study Sponsor'][56]
- ⇄57 => string (25) "Kartos Therapeutics, Inc."$items[6]['Study Sponsor'][57]
- ⇄58 => string (33) "Our Lady's Hospice & Care Service"$items[6]['Study Sponsor'][58]
- ⇄59 => string (27) "St Vincents Hospital Sydney"$items[6]['Study Sponsor'][59]
- ⇄60 => string (52) "University Hospitals Birmingham NHS Foundation Trust"$items[6]['Study Sponsor'][60]
- ⇄61 => string (21) "University of Warwick"$items[6]['Study Sponsor'][61]
- ⇄62 => string (22) "QBiotics Group Limited"$items[6]['Study Sponsor'][62]
- ⇄63 => string (11) "Seagen Inc."$items[6]['Study Sponsor'][63]
- ⇄64 => string (6) "Pfizer"$items[6]['Study Sponsor'][64]
- ⇄65 => string (60) "University Hospitals Bristol and Weston NHS Foundation Trust"$items[6]['Study Sponsor'][65]
- ⇄66 => string (18) "Cardiff University"$items[6]['Study Sponsor'][66]
- ⇄67 => string (32) "Anthony Nolan Research Institute"$items[6]['Study Sponsor'][67]
- ⇄68 => string (49) "Sheffield Teaching Hospitals NHS Foundation Trust"$items[6]['Study Sponsor'][68]
- ⇄69 => string (22) "PAREXEL International "$items[6]['Study Sponsor'][69]
- ⇄70 => string (41) "Nottingham University Hospitals NHS Trust"$items[6]['Study Sponsor'][70]
- ⇄71 => string (18) "EHA Lymphoma Group"$items[6]['Study Sponsor'][71]
- ⇄72 => string (20) "Newcastle University"$items[6]['Study Sponsor'][72]
- ⇄73 => string (34) "Karyopharm Therapeutics, Inc (USA)"$items[6]['Study Sponsor'][73]
- ⇄74 => string (15) "Astellas Pharma"$items[6]['Study Sponsor'][74]
- ⇄75 => string (13) "Telios Pharma"$items[6]['Study Sponsor'][75]
- ⇄76 => string (8) "iOnctura"$items[6]['Study Sponsor'][76]
- ⇄77 => string (24) "Neurotrials Research Inc"$items[6]['Study Sponsor'][77]
- ⇄78 => string (15) "GlaxoSmithKline"$items[6]['Study Sponsor'][78]
- ⇄79 => string (53) "International Extranodal Lymphoma Study Group (IELSG)"$items[6]['Study Sponsor'][79]
- ⇄80 => string (13) "Genetech Inc."$items[6]['Study Sponsor'][80]
- ⇄81 => string (23) "AstraZeneca AB - Sweden"$items[6]['Study Sponsor'][81]
- ⇄82 => string (23) "BeOne Medicines UK, Ltd"$items[6]['Study Sponsor'][82]
- ⇄83 => string (32) "Janssen Research and Development"$items[6]['Study Sponsor'][83]
- ⇄84 => string (0) ""$items[6]['Study Sponsor'][84]
- ⇄85 => string (16) "Astra Zeneca plc"$items[6]['Study Sponsor'][85]
- ⇄86 => string (14) "CRUK,Unicancer"$items[6]['Study Sponsor'][86]
- ⇄0 => string (23) "University of Liverpool"
- ⇄Order => integer 6$items[6]['Order']
- ⇄⧉Study Sponsor => array (87)
- ⇄⧉7 => array (2)$items[7]
- ⇄⧉Planned End Date => array (54)$items[7]['Planned End Date']
- ⇄0 => string (0) ""$items[7]['Planned End Date'][0]
- ⇄1 => string (10) "30/09/2025"$items[7]['Planned End Date'][1]
- ⇄2 => string (10) "01/07/2028"$items[7]['Planned End Date'][2]
- ⇄3 => string (10) "17/10/2025"$items[7]['Planned End Date'][3]
- ⇄4 => string (10) "01/03/2026"$items[7]['Planned End Date'][4]
- ⇄5 => string (10) "30/06/2033"$items[7]['Planned End Date'][5]
- ⇄6 => string (10) "30/04/2027"$items[7]['Planned End Date'][6]
- ⇄7 => string (10) "01/08/2025"$items[7]['Planned End Date'][7]
- ⇄8 => string (10) "03/08/2026"$items[7]['Planned End Date'][8]
- ⇄9 => string (10) "28/02/2030"$items[7]['Planned End Date'][9]
- ⇄10 => string (10) "31/12/2025"$items[7]['Planned End Date'][10]
- ⇄11 => string (10) "31/12/2026"$items[7]['Planned End Date'][11]
- ⇄12 => string (10) "01/01/2026"$items[7]['Planned End Date'][12]
- ⇄13 => string (10) "31/05/2025"$items[7]['Planned End Date'][13]
- ⇄14 => string (10) "06/02/2026"$items[7]['Planned End Date'][14]
- ⇄15 => string (10) "18/07/2025"$items[7]['Planned End Date'][15]
- ⇄16 => string (10) "01/07/2027"$items[7]['Planned End Date'][16]
- ⇄17 => string (10) "30/11/2025"$items[7]['Planned End Date'][17]
- ⇄18 => string (10) "31/03/2025"$items[7]['Planned End Date'][18]
- ⇄19 => string (10) "12/12/2025"$items[7]['Planned End Date'][19]
- ⇄20 => string (10) "17/09/2030"$items[7]['Planned End Date'][20]
- ⇄21 => string (10) "30/11/2029"$items[7]['Planned End Date'][21]
- ⇄22 => string (10) "28/02/2026"$items[7]['Planned End Date'][22]
- ⇄23 => string (10) "28/02/2025"$items[7]['Planned End Date'][23]
- ⇄24 => string (10) "31/03/2028"$items[7]['Planned End Date'][24]
- ⇄25 => string (10) "11/09/2026"$items[7]['Planned End Date'][25]
- ⇄26 => string (10) "31/01/2026"$items[7]['Planned End Date'][26]
- ⇄27 => string (10) "16/02/2026"$items[7]['Planned End Date'][27]
- ⇄28 => string (10) "30/06/2025"$items[7]['Planned End Date'][28]
- ⇄29 => string (11) " 25/11/2020"$items[7]['Planned End Date'][29]
- ⇄30 => string (10) "31/12/2027"$items[7]['Planned End Date'][30]
- ⇄31 => string (10) "01/11/2025"$items[7]['Planned End Date'][31]
- ⇄32 => string (10) "31/10/2026"$items[7]['Planned End Date'][32]
- ⇄33 => string (10) "30/06/2026"$items[7]['Planned End Date'][33]
- ⇄34 => string (10) "31/07/2025"$items[7]['Planned End Date'][34]
- ⇄35 => string (10) "31/03/2026"$items[7]['Planned End Date'][35]
- ⇄36 => string (10) "01/04/2029"$items[7]['Planned End Date'][36]
- ⇄37 => string (10) "31/05/2029"$items[7]['Planned End Date'][37]
- ⇄38 => string (10) "30/07/2032"$items[7]['Planned End Date'][38]
- ⇄39 => string (10) "25/02/2025"$items[7]['Planned End Date'][39]
- ⇄40 => string (10) "31/05/2027"$items[7]['Planned End Date'][40]
- ⇄41 => string (10) "11/04/2026"$items[7]['Planned End Date'][41]
- ⇄42 => string (10) "18/07/2028"$items[7]['Planned End Date'][42]
- ⇄43 => string (10) "01/04/2026"$items[7]['Planned End Date'][43]
- ⇄44 => string (10) "01/04/2028"$items[7]['Planned End Date'][44]
- ⇄45 => string (11) " 19/11/2012"$items[7]['Planned End Date'][45]
- ⇄46 => string (10) "28/09/2026"$items[7]['Planned End Date'][46]
- ⇄47 => string (10) "01/03/2025"$items[7]['Planned End Date'][47]
- ⇄48 => string (10) "01/05/2025"$items[7]['Planned End Date'][48]
- ⇄49 => string (10) "03/09/2030"$items[7]['Planned End Date'][49]
- ⇄50 => string (10) "01/06/2032"$items[7]['Planned End Date'][50]
- ⇄51 => string (10) "01/12/2028"$items[7]['Planned End Date'][51]
- ⇄52 => string (10) "26/01/2026"$items[7]['Planned End Date'][52]
- ⇄53 => string (10) "24/07/2026"$items[7]['Planned End Date'][53]
- ⇄0 => string (0) ""
- ⇄Order => integer 7$items[7]['Order']
- ⇄⧉Planned End Date => array (54)
- ⇄⧉0 => array (2)
